Year All202620252024202320222021202020192018201720162014201320112010 July 27, 2020 Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations July 20, 2020 Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer July 16, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities July 1, 2020 Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities June 24, 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers May 26, 2020 Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in June May 13, 2020 Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities May 5, 2020 Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference May 4, 2020 Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results
July 27, 2020 Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations
July 20, 2020 Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer
July 16, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism
July 1, 2020 Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities
July 1, 2020 Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities
June 24, 2020 Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers
May 13, 2020 Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities
May 5, 2020 Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference
